Central European Cooperative Oncology Group
Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Central European Cooperative Oncology Group
- Target Recruit Count
- 5
- Registration Number
- NCT01918761
- Locations
- 🇦🇹
Medizinische Universität Graz Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹Universitätsklinik für Innere Medizin I, Innsbruck, Austria
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Central European Cooperative Oncology Group
- Target Recruit Count
- 9
- Registration Number
- NCT01161368
- Locations
- 🇦🇹
Dep. of Medicine I , Division of Oncology, Vienna, Austria
🇭🇺National Institute of Oncology, Budapest, Hungary
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Central European Cooperative Oncology Group
- Target Recruit Count
- 564
- Registration Number
- NCT00600340
- Locations
- 🇦🇹
LKH Leoben, Leoben, Austria
🇦🇹Hospital Barmherzige Schwestern, Linz, Austria
🇦🇹AKH Linz, Dep. of Oncology, Linz, Austria
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Central European Cooperative Oncology Group
- Target Recruit Count
- 151
- Registration Number
- NCT00479752
- Locations
- 🇦🇹
LKH Leoben, Abt. für Innere Medizin, Leoben, Steiermark, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
🇧🇦Institute of Oncology Sarajevo, Sarajevo, Bosnia and Herzegovina
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Cancer
- Interventions
- Drug: Capecitabine, Interferon, Interleukin
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- Central European Cooperative Oncology Group
- Target Recruit Count
- 172
- Registration Number
- NCT00311467
- Locations
- 🇦🇹
Univ. Klinik f. Innere Medizin, Abt. Onkologie, Vienna, Austria
- Prev
- 1
- 2
- 3
- Next